Key Highlights:
- FDA restricts Moderna's COVID-19 vaccine use, impacting target demographics.
- Wall Street analysts show a mixed outlook with varied price targets.
- Current "Hold" recommendation based on average brokerage insights.
The FDA has imposed limitations on the use of Moderna Inc.'s (MRNA) COVID-19 vaccine, narrowing its availability to seniors and individuals with underlying health conditions. This decision comes despite initial staff recommendations advocating for broader approval for individuals aged 12 and older, reflecting diminishing COVID threats. Investors should closely monitor these regulatory developments, as they could significantly impact Moderna's market reach and stock dynamics.
Wall Street Analysts' Perspective on Moderna
According to the projections from 20 analysts, the average target price for Moderna Inc. (MRNA) is set at $46.80. Notably, the high and low estimates show considerable variation, standing at $198.00 and $20.00 respectively. The average estimated target suggests a potential upside of 53.98% from the current stock price of $30.39. For a more in-depth analysis and detailed data, investors can visit the Moderna Inc. (MRNA, Financial) Forecast page.
Brokerage Recommendations
Moderna Inc.'s current standing among 26 brokerage firms reflects an average recommendation score of 3.0, aligning with a "Hold" status. This rating falls within a scale where 1 signifies a Strong Buy, transitioning up to 5, which indicates a Sell. The implication of this score suggests a cautious stance among analysts, underpinning a balanced view of Moderna's future performance in the market.
GF Value Estimation
Utilizing GuruFocus estimates, the projected GF Value for Moderna Inc. (MRNA) in the coming year is calculated at $20.53. This suggests a potential downside of 32.45% from the current trading price of $30.3942. The GF Value is a proprietary metric from GuruFocus, calculated considering historical trading multiples, past business growth, and future business performance estimates. Investors seeking a comprehensive evaluation can refer to the Moderna Inc. (MRNA, Financial) Summary page for further information.
